XML 89 R74.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION -Schedule of Disaggregates of Total Net Product Revenues Based on Patient Location (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Revenue $ 2,096,039 $ 1,846,275 $ 1,860,455 [1]
Total net product revenues      
Disaggregation of Revenue [Line Items]      
Revenue 2,042,025 1,783,498 1,805,861 [1]
Marketed by Company | Total net product revenues marketed by the Company      
Disaggregation of Revenue [Line Items]      
Revenue 1,913,603 1,660,733 1,675,754
Marketed by Company | Total net product revenues marketed by the Company | United States      
Disaggregation of Revenue [Line Items]      
Revenue 684,284 657,700 756,863
Marketed by Company | Total net product revenues marketed by the Company | Europe      
Disaggregation of Revenue [Line Items]      
Revenue 650,952 558,952 498,725
Marketed by Company | Total net product revenues marketed by the Company | Latin America      
Disaggregation of Revenue [Line Items]      
Revenue 266,801 191,151 205,862
Marketed by Company | Total net product revenues marketed by the Company | Rest of world      
Disaggregation of Revenue [Line Items]      
Revenue 311,566 252,930 214,304
Marketed by Sanofi | ALDURAZYME net product revenues marketed by Sanofi      
Disaggregation of Revenue [Line Items]      
Revenue $ 128,422 $ 122,765 $ 130,107
[1] Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.